1,720,982 research outputs found
Cancer in pregnancy. An association to make one shiver-highlights from 'Cancer in pregnancy. 15 years after', 10-11 October 2019, Milan, Italy
Full text linkAlthough rare, the treatment of pregnant women with cancer remains a challenging situation that requires strict collaboration between different specialities and experts in different fields. Frequent lack of experience and knowledge about this condition could lead to late diagnosis, imprecise management, suboptimal treatment, and foetal and maternal harm. Until recently, the choice for a woman diagnosed with cancer during pregnancy was either to sacrifice the foetus by administering effective treatment to the mother or to risk potential harm to the mother by withholding chemotherapy. This conference report aims to summarise all different aspects of cancer and pregnancy discussed at this 2-day meeting. Data on the safety (for mother and child) of chemotherapy administered after the first trimester of pregnancy are accumulating together with the recommendation to bring pregnancy as close as possible to its natural duration. Several aspects such as the poor prognosis of breast cancer diagnosed in the year after delivery and the delayed growth of foetuses exposed to chemotherapy despite the quasi-normal duration of pregnancy require further investigation. In this apparently tragic situation, results are excellent and comforting data accumulate so that we can transmit an optimistic feeling to women facing cancer during pregnancy
Pregnancy and lactation. Risk or protective factors for breast cancer?
No full textPregnancy and lactation represent the most effective protective elements against breast cancer; counter-intuitively breast cancer incidence shows a small but noticeable increase up to 5 years after delivery. The cumulative effect is however favourable and women show a reduction in breast cancer risk which is proportional to the total duration of lactation and to the number of full-term pregnancies
DTC chemotherapy regimen is associated with higher occurrence of premature ovarian failure in women of reproductive age with breast cancer
No full textRisk of cancer after assisted reproduction: a review of the available evidences and guidance to fertility counselors
Full text linkInfertile women requiring ovarian stimulation and assisted reproduction techniques (ART) are faced with difficult issues. The fear that using hormones could increase their risk of cancer is the most significant. One of the main challenges for assessing cancer risk after ART is the difficulty to separate it from the underlying condition of infertility per se. The delay or the inability to achieve a pregnancy is an important risk factor for breast, endometrial and ovarian cancer. We analyzed the current literature on the topic
Lactation during and after breast cancer
No full textBreastfeeding is an important aspect of mother-newborn relationship and is of great benefit for the baby. Unfortunately, many drugs taken by the mother may pass into her milk and exert an effect on the newborn. Very limited data is available and a cautionary approach is warranted especially when the woman receives anticancer treatment including chemotherapy, hormonal treatment and the recently introduced target agents as well as monoclonal antibodies. In all these conditions breastfeeding should be put on hold. More and more often physicians are faced with women that are pregnant years after the diagnosis of cancer: this has long been considered dangerous for the mother, but data show that prognosis is definitely not worse. If the woman is no longer being actively treated, breastfeeding is advisable every time it is possible, even if patients that received breast radiation may be unable to produce a sufficient amount of milk on that side
In vitro evaluation of drugs active in colorectal carcinoma therapy: A preliminary study in view of the clinical use of chemosensitivity tests
No full textIn vitro evaluation of drugs active in colorectal carcinoma therapy: A preliminary study in view of the clinical use of chemosensitivity test
Review Article a Multidisciplinary Evaluation for Advanced Supportive Care of Breast Cancer Patients
No full textBackground: The prevalence of cancer is increasing, and this is the consequence of the rising incidence of tumours but also of the more effective treatments received. This implies that there are more and more persons that receive medical anticancer therapies and that are interested in maintaining their quality of life. Many oncological treatments, including chemotherapy, immunotherapy, surgery and radiotherapy, and combined therapy are associated with cutaneous toxicity. This is particularly relevant when new therapies are used since these may cause new and unexpected side effects that may be short-lived but, in some cases, may become chronic or permanent. Patients often seek advice with their oncologists on what can be done and what cannot be done. Notably, many of the cutaneous side effects can be prevented or reduced by adequate interventions. Summary: The aim of this review is to highlight how oncological patients may benefit from a closer collaboration between specialists in different branches. We will focus on women with breast cancer since we think that they may derive a special benefit from this collaboration, but we will analyse other cancers in future papers. Key Messages: The working group was created with two specific aims: to help the oncologist in the prevention and management of cutaneous toxicity and to support patients in this phase of their lives, including nutritional assessment and dietary support
First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother. A case study
Full text linkBackground Breast cancer represents the most frequent neoplasm diagnosed in women of childbearing age. When the tumour is oestrogen receptor-positive, tamoxifen is among the recommended endocrine treatments. Lactating women are advised not to breastfeed while receiving tamoxifen. However, information about tamoxifen transfer into breast milk is lacking. Methods We measured the concentration of tamoxifen and its metabolites by liquid chromatography-tandem mass spectrometry in the milk of a nursing mother that was treated for pregnancy-associated breast cancer diagnosed a few months after delivery. She was advised not to breastfeed her child and she collected milk samples for 23 days while the baby was fed with formula. Results Tamoxifen concentrations in milk increased reaching a maximum of 214 nM. The two active metabolitesZ-4-hydroxy-tamoxifen and Z-endoxifen, could not be quantified in milk the first days after tamoxifen intake, but increased over time and reached clinically significant levels after day 18. Conclusion This study demonstrates for the first time in human that tamoxifen and its metabolites transfer into milk. Since tamoxifen has a complete oral bioavailability, a long half-life (>7 days) and may interfere with the normal development of the infant, mothers should not breastfeed during tamoxifen treatment
Comparison of 18F FDG PET-CT AND CECT in pretreatment staging of adults with Hodgkin's lymphoma
No full text- …
